


PHARMACEUTICAL 2022

G1 Therapeutics Inc. Rank 338 of 475







PHARMACEUTICAL 2022

G1 Therapeutics Inc. Rank 338 of 475



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of G1 Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is -244%, being 33% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	243,565
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,613
Liabilities, Non-Current	6,750
Other Assets	8,516
Other Compr. Net Income	0
Other Expenses	2,941
Other Liabilities	76,190
Other Net Income	-4,970
Property and Equipment	2,013
Research and Development	76,225
Revenues	31,476
Selling, General and Administrative Expense	95,692

Output Variable	Value in 1000 USD
Assets	254,094
Liabilities	110,553
Expenses	174,858
Stockholders Equity	143,541
Net Income	-148,352
Comprehensive Net Income	-148,352
Economic Capital Ratio	-244%